148 related articles for article (PubMed ID: 14977214)
21. HIV-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia: gene expression review.
Minagar A; Shapshak P; Duran EM; Kablinger AS; Alexander JS; Kelley RE; Seth R; Kazic T
J Neurol Sci; 2004 Sep; 224(1-2):3-17. PubMed ID: 15450765
[TBL] [Abstract][Full Text] [Related]
22. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis.
Rajda C; Bergquist J; Vécsei L
J Neural Transm Suppl; 2007; (72):323-9. PubMed ID: 17982910
[TBL] [Abstract][Full Text] [Related]
23. The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review.
Almeida-Santos AF; Kangussu LM; Campagnole-Santos MJ
Protein Pept Lett; 2017 Nov; 24(9):841-853. PubMed ID: 28828974
[TBL] [Abstract][Full Text] [Related]
24. 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system.
Colín-González AL; Maldonado PD; Santamaría A
Neurotoxicology; 2013 Jan; 34():189-204. PubMed ID: 23219925
[TBL] [Abstract][Full Text] [Related]
25. [Biochemical studies on AIDS dementia complex--possible contribution of quinolinic acid during brain damage].
Saito K
Rinsho Byori; 1995 Sep; 43(9):891-901. PubMed ID: 7474452
[TBL] [Abstract][Full Text] [Related]
26. Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects.
Hertelendy P; Toldi J; Fülöp F; Vécsei L
Curr Med Chem; 2018; 25(42):5945-5957. PubMed ID: 29532751
[TBL] [Abstract][Full Text] [Related]
27. Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system.
Moroni F; Carpenedo R; Chiarugi A
Adv Exp Med Biol; 1996; 398():203-10. PubMed ID: 8906267
[No Abstract] [Full Text] [Related]
28. Editorial: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders.
Anderson G
Curr Pharm Des; 2016; 22(8):947-8. PubMed ID: 26725229
[No Abstract] [Full Text] [Related]
29. Kynurenine metabolism in central nervous system in experimental chronic renal failure.
Topczewska-Bruns J; Pawlak D; Tankiewicz A; Chabielska E; Buczko W
Adv Exp Med Biol; 2003; 527():177-82. PubMed ID: 15206730
[TBL] [Abstract][Full Text] [Related]
30. Endogenous kynurenines as targets for drug discovery and development.
Stone TW; Darlington LG
Nat Rev Drug Discov; 2002 Aug; 1(8):609-20. PubMed ID: 12402501
[TBL] [Abstract][Full Text] [Related]
31. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
[TBL] [Abstract][Full Text] [Related]
32. Relevance of protein nitration in brain injury: a key pathophysiological mechanism in neurodegenerative, autoimmune, or inflammatory CNS diseases and stroke.
Sarchielli P; Galli F; Floridi A; Floridi A; Gallai V
Amino Acids; 2003 Dec; 25(3-4):427-36. PubMed ID: 14661102
[TBL] [Abstract][Full Text] [Related]
33. Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection.
Cosimo Melcangi R; Garcia-Segura LM
Horm Behav; 2010 Jan; 57(1):2-11. PubMed ID: 19524584
[TBL] [Abstract][Full Text] [Related]
34. A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma.
Orsatti L; Speziale R; Orsale MV; Caretti F; Veneziano M; Zini M; Monteagudo E; Lyons K; Beconi M; Chan K; Herbst T; Toledo-Sherman L; Munoz-Sanjuan I; Bonelli F; Dominguez C
J Pharm Biomed Anal; 2015 Mar; 107():426-31. PubMed ID: 25668794
[TBL] [Abstract][Full Text] [Related]
35. Kynurenines: from the perspective of major psychiatric disorders.
Myint AM
FEBS J; 2012 Apr; 279(8):1375-85. PubMed ID: 22404766
[TBL] [Abstract][Full Text] [Related]
36. Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo V
Nat Rev Drug Discov; 2008 May; 7(5):438-55. PubMed ID: 18446159
[TBL] [Abstract][Full Text] [Related]
37. [Metabotropic glutamate receptors as targets for new drug development].
Arkhipov VI; Kapralova MV
Eksp Klin Farmakol; 2011; 74(10):46-52. PubMed ID: 22238988
[TBL] [Abstract][Full Text] [Related]
38. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
Al-Shamahi A; Kirkham K; Hookes L
IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
[TBL] [Abstract][Full Text] [Related]
39. Role of p53 in neurodegenerative diseases.
Chang JR; Ghafouri M; Mukerjee R; Bagashev A; Chabrashvili T; Sawaya BE
Neurodegener Dis; 2012; 9(2):68-80. PubMed ID: 22042001
[TBL] [Abstract][Full Text] [Related]
40. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
Stone TW; Forrest CM; Darlington LG
FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
